Trial Profile
The Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD19 chimeric antigen receptor T cell therapy Shanghai Unicar Therapy Bio-medicine Technology (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 21 Mar 2018 New trial record